Back to top

Avalo Therapeutics initiated with an Outperform at Leerink

Leerink initiated coverage of Avalo Therapeutics (AVTX) with an Outperform rating and $38 price target With de-risked Phase 2 data in hand for abda...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Avalo Therapeutics, Inc. (AVTX)